Podcasts about iquity

An interview with Chase Spurlock, PhD, founder and CEO of Decode Health. He founded Decode Health in 2019 and its predecessor company, IQuity, in 2015. Chase talks with Don Seamons about how machine learning solutions can use data to help patients by accelerating the time to diagnosis and finding the best treatments.

IQuity Analytics is the first and only data analytics solution that can identify undetected, uncontrolled or misdiagnosed autoimmune conditions. Our patent-pending technology can identify autoimmune patients and help reduce the guaranteed risk hidden in most health plans. Combining the investigative minds of immunologists with the analytical speed and efficiency of a supercomputer, IQuity's analytics solution detects and monitors autoimmune disease earlier and more effectively than anything else on the market. Autoimmune disease affects 23.5M Americans – it's right up there with heart disease, diabetes, and cancer. These diseases are difficult to detect because they can mimic many others diseases. It affects you or someone you know – these are disease like multiple sclerosis, rheumatoid arthritis, Crohn's – and more. Autoimmune diseases are incurable, but can be treated. With early detection and monitoring, patients have the best opportunity to minimize disability and live happier, healthier lives. New technologies to help doctors diagnose and treat chronic illness. Artificial intelligence and machine learning. Use of these techniques can help doctors find and treat chronic illnesses, like autoimmune disease, more effectively. Lowering the cost of healthcare through the use of cutting edge technologies - Autoimmune disease is a guaranteed financial risk for those who shoulder the cost of healthcare, Self-insured employers and Payers – insurance companies. IQuity recently launched its platform to help these payers find and fix their addressable, autoimmune disease risk. Currently piloting with customers. Can identify people who have an undetected, misdiagnosed, or uncontrolled autoimmune disease. This is just the beginning – this platform can be trained to go after virtually any disease. Learn more: https://iquity.com/

At the height of the economic recession in 2009, Michael Brody-Waite quit his job at a Fortune 50 company to become an aspiring entrepreneur. Looking back now, he humbly admits, he had no idea what he was doing. "I know it says I'm CEO, but I had no idea how to be a CEO, how to run the business … We were creating an industry that had never been done before without any investors or advisors." But 16 years of sobriety and three powerful words - experience, strength and hope - gave Brody-Waite the unwavering will to push on. "For me, getting clean was the hardest thing that I ever did, and so I started saying, well, how did I do that? And I went back to those words. I needed to find experience, strength and hope as an entrepreneur." Six years later, his startup was bought by a publicly traded company. Brody-Waite is now the CEO of the Nashville EC, giving back to the very organization that helped him years ago. Only this time, he is offering his personal experiences as a mentor, his strengths navigating the often confusing community waters and a hope to better connect the local entrepreneur ecosystem. "In recovery, I was always taught you can't keep anything unless you give it away." Included in this episode are stories and perspectives from local entrepreneurs: LeShane Greenhill (Founder and CEO of Sagents and Sales Cocktail), Julia Polk (Chief Strategy Officer and CFO of IQuity) and Shawn Glinter (Founder and CEO of Pendant Biosciences). All three attribute their success to the mentorship they received, and today each pay it forward serving in a variety of mentor roles.

How do we balance the demands of work and family? It’s a dilemma most career women face, and one that Julia Polk confronted when she had two young daughters at home. Her solution would take her on a non-linear journey to success as an investment banker and healthcare executive. “I’ve come and gone a bunch of times” from the workforce, she says. “I think my children benefited from it — I know I did.” Today Julia is chief financial officer of healthcare startup IQuity and a valued mentor to many healthcare entrepreneurs.   In this episode Julia explains why she was lucky to have female role models early in her career and what she did to stay connected during her extended breaks from the workforce. She also tells us about the value of diversity in leadership teams, the issues women face in raising capital for a business, how to overcome the imposter syndrome, why the first step for any startup is understanding its customers and why she thinks younger generations will have more opportunities for flextime work.

Artificial intelligence is about to change the entire healthcare landscape. And that might very well include how MS is diagnosed, treated, and managed. It's even beginning to impact the way some MS research is being conducted. My guest is the founder and CEO of iQuity, Dr. Chase Spurlock. iQuity is using its expertise in machine learning to improve patient care, drive the creation of new therapies, and reduce the costs associated with managing chronic illness, including multiple sclerosis.      We're also talking about the important but sometimes overlooked difference between MS facts and MS beliefs. We'll tell you about the safety alert that the FDA has issued for Lemtrada, and new survey research from the MS Society in the UK that shows the majority of people living with MS are living with feelings of loneliness and isolation.   You'll hear about new study data that shows the gender differences in MS have some age-related fine points that are worth noting, and we'll tell you about a Phase 3 clinical trial that's looking at the effectiveness of high-dose biotin in slowing or stopping MS progression for people living with progressive MS.   We have a lot to talk about! Are you ready for RealTalk MS?! ___________ The Difference Between MS Facts & MS Beliefs   0:22 How AI is About to Disrupt Healthcare 4:21 FDA Issues a Safety Alert for Lemtrada  7:40 MS Society in the UK Survey Research Shows 3 in 5 People Living with MS are Living with Loneliness  9:51 Gender Differences in MS Vary with Age & MS Subtype  13:40 MedDay Phase 3 Clinical Trial for Progressive MS Fully Enrolled  15:55 My Interview with iQuity CEO, Dr. Chase Spurlock  17:50  ___________ LINKSIf your podcast app doesn’t allow you to click on these links, you’ll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Download the RealTalk MS App for iOS Download the RealTalk MS App for Android FDA Warns About Rare But Serious Risks of Stroke & Blood Vessel Wall Tears with Multiple Sclerosis Drug Lemtrada Age-Dependent Variation of Female Preponderance Across Different Phenotypes of Multiple Sclerosis: A Retrospective Cross-Sectional Study iQuity   Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 68 Hosted By: Jon Strum Guest: Dr. Chase Spurlock Tags: MS, MultipleSclerosis, MS, RealTalkMS, mssocietyUK, AI, Lemtrada, MedDay, Biotin, iQuity

We take advantage of digital tools every day to make our lives easier. But when it comes to managing our health, there's still a long way to go. That's why the MS Society in the UK commissioned a report titled "Improving Care for People with MS: The Potential of Data & Technology". That report has just been published, and we're discussing some of the observations and recommendations contained in this remarkable report with my special guest, Michelle Mitchell, CEO of the MS Society in the UK.     We're also talking about a new artificial intelligence-based data analysis platform that can diagnose MS sooner than traditional diagnostic methods, with 90% accuracy. We'll tell you about a new poll that shows that the overwhelming majority of American voters support protecting the rights of people with pre-existing medical conditions, in spite of the Justice Department's efforts to remove those protections. We're taking a look at new research that could change the game when it comes to myelin repair. And we'll tell you about two different MS research studies that are recruiting participants to complete a 15-minute online survey.   We have a lot to talk about. Are you ready for RealTalk MS? ___________ AI-Enabled Data Analysis Platform Can Diagnose MS  1:37 Latest Poll Shows Overwhelming Voter Support For Protecting Patients With Pre-Existing Medical Conditions in the U.S.  3:40 Groundbreaking Research Highlights Different Paths to Myelin Repair  7:24 2 Research Studies Recruiting Participants for Online Surveys  12:07 Interview with Michelle Mitchell  13:49 ___________ LINKSIf your podcast app doesn’t show these links, you’ll find them in the show notes at www.RealTalkMS.com iQuity Friend of the Court Brief Filed in U.S. District Court by the National MS Society, American Cancer Society, the American Diabetes Association, the American Heart Association, and the American Lung Association University of Melbourne Research Devising New Way to Repair Myelin CWRU Research Demonstrates Blocking Cholesterol Enzyme Stimulates Myelin Repair Study Opportunity: Coping Styles in MS & Other Autoimmune Diseases Study Opportunity: Treatment Options For Walking Difficulties in MS Improving Care for People with MS: The Potential of Data & Technology MS Society of Great Britain   Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 46 Hosted By: Jon Strum Guest: Michelle Mitchell Tags: MS, MultipleSclerosis, MSResearch, iQuity, ProtectOurCare, mssocietyuk, nuffieldtrust, mscare, RealTalkMS

**This interview was recorded in the late spring of 2017. IsolateMS and several of the other disease state diagnostics mentioned in this episode are now available. Getting an MS diagnosis has been more about exclusion than a definitive answer. Until now. IQuity, Inc. has cracked the code. They introduced a simple blood test that provides an answer in a week with a better than 90 percent accuracy rate! This. Is. Big. Most of us with an MS diagnosis went through a battery of tests - including a lumbar puncture - to settle on a diagnosis of MS likelihood. And even that could take years to get. Listen as IQuity, Inc. CEO Chase Spurlock and CFO and Chief Strategy Officer Julia Polk describe the process of discovering this amazing technology, and all of the potential it has for revolutionizing diagnostics for Multiple Sclerosis and other previously difficult to diagnose diseases.  Hear questions posed about differentiating types of MS or predicting whether or not our relatives are at risk. Learn how to get the test for yourself or a loved one - and how to get patient assistance.  "The immune system sees things before the physical manifestation of the disease."  ~~Chase Spurlock Be sure to sign up for email updates on articles, podcast episodes and breaking MS news right here: Sign Me Up Join us for daily discussions and support on the FUMS Facebook page.

Dr. Chase Spurlock is CEO of IQuity, a specialty diagnostic technology company in Nashville, TN, as well as a faculty member in Medicine at Vanderbilt University. He received his B.S. in Biology at the University of the South in Sewanee, TN. Chase then completed his PhD in Microbiology and Immunology at Vanderbilt University for which he was awarded the Sidney P. Colowick award for outstanding research. Chase is here with us today to talk about his research, his company, and his life.